XNAS
COLL
Market cap717mUSD
Oct 08, Last price
22.11USD
1D
0.82%
1Q
-37.24%
Jan 2017
42.00%
IPO
70.73%
Name
Collegium Pharmaceutical Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Key people
Vikram Karnani
President, Chief Executive Officer, Director · since 2024
Dean Patras
Chief People Officer · since 2025
Scott Dreyer
Executive Vice President, Chief Commercial Officer · since 2018
Jane Gonnerman
Executive Vice President - Strategy and Corporate Development · since 2025
Executive Vice President, Chief Medical Officer · since 2022
Colleen Tupper
Chief Financial Officer, Executive Vice President · since 2021
David Dieter
Executive Vice President, General Counsel, Corporate Secretary · since 2025
Rita Balice-Gordon
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2016
Independent Director · since 2014
Independent Director · since 2025
Independent Director · since 2025
Independent Chairman of the Board · since 2025
Legal address
C/O Corporation Service Company
100 Shockoe Slip Fl 2
Richmond, VA 23219
US
100 Shockoe Slip Fl 2
Richmond, VA 23219
US
Headquarters
100 Technology Center Dr Ste 300
Stoughton, MA 02072
US
Stoughton, MA 02072
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||